论文部分内容阅读
对68例鼻恶性肿瘤病人进行血小板聚集试验,并以100例正常人和10例鼻良性肿瘤病人为对照。结果发现恶性肿瘤疗前组、复发组、远隔转移组血小板最大聚集率(MAR)均数高于正常组、良性肿瘤组和疗后组(P<0.05);疗前组中MAR均数则随肿瘤的临床分期的进展而增高;有效治疗后降低或恢复正常。表明恶性肿瘤可引起血小板聚集增强。研究提示血小板聚集功能可作为观察、判断肿瘤性质、发展、疗效、预后的参考指标。本文对恶性肿瘤病人血小板聚集增强的机制、血小板在肿瘤生长、转移中的作用等方面进行了讨论,并展望了血小板抑制剂抗肿瘤的临床应用。
Platelet aggregation tests were performed on 68 cases of nasal cancer patients and 100 controls and 10 patients with benign nasal tumors were used as controls. The results showed that the mean platelet aggregation rate (MAR) was higher in the pretreatment group, relapse group, and distal metastasis group than in the normal group, benign tumor group, and posttreatment group (P<0.05); the mean MAR in the pretreatment group was Increases with the progression of the clinical stage of the tumor; decreases or returns to normal after effective treatment. This indicates that malignant tumors can cause increased platelet aggregation. The study suggests that platelet aggregation function can be used as a reference indicator to observe and judge the nature, development, efficacy, and prognosis of tumors. This article discusses the mechanism of platelet aggregation enhancement in patients with malignant tumors, the role of platelets in tumor growth and metastasis, and looks forward to the clinical application of platelet inhibitor anti-tumor.